Company: LGN
Filing Date: 2025-12-09
Form Type: S-1
Source: 0001193125-25-312729
Chunk: 97

Company: Legence Corp.
Filing Date: 2025-12-09
Form: S-1
Chunk 97
---
 forth
in the Purchase Agreement, the Purchaser will acquire all of the outstanding Bowers Interests from NewCo in exchange for an aggregate purchase price of approximately $475 million, consisting of: (i) approximately $325 million in cash, subject
to certain purchase price adjustments and (ii) approximately 2.55 million shares of Class A Common Stock, which shares will be subject to applicable restrictive legends pursuant to the Securities Act and will be subject to a lock-up on transfers,
subject to certain exceptions, until (and including) March 10, 2026 (the “Stock Consideration”).

In addition, on the
terms and subject to the conditions set forth in the Purchase Agreement, on the Deferred Consideration Date, NewCo will receive the Deferred Consideration, payable in either, or any combination of, as determined in the Purchaser’s sole
discretion, (i) cash or (ii) shares of Class A Common Stock. The amount of any shares of Class A Common Stock issued in connection with the satisfaction of the Deferred Consideration payment obligation (any such shares, the “Deferred
Consideration Shares”) will be determined based on the volume weighted average sales price of the Class A Common Stock, as traded on Nasdaq, calculated for the 10 trading day period ending on the last trading day that occurs at least 3 days
prior to the Deferred Consideration Date. Any Deferred Consideration Shares issued shall be subject to applicable restrictive legends pursuant to the Securities Act.

The Closing is subject to the satisfaction or waiver of customary closing conditions set forth in the Purchase Agreement, including (a) the
accuracy of the representations and warranties of each party (subject to specified materiality standards and customary qualifications), (b) compliance by each party in all material respects with their respective covenants and (c) the expiration or
termination of all waiting periods imposed under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The Closing is not conditioned on our receipt of any debt or equity financing.

Initial Public Offering

On September 15,
2025, we completed our IPO, in which we issued and sold 29,487,627 shares of our Class A Common Stock (including the partial exercise of the underwriters’ overallotment option) at a public offering price of $28.00 per share. We received net
proceeds of approximately $780.2 million from sales of shares of Class A Common Stock in the IPO, after deducting underwriting